After screening and confirmed by Oncomine dataset (https://www.oncomine.org) and UALCAN (http://ualcan.path.uab.edu), epidermal growth factor receptor (EFGR) was deemed to a key factor and potential target for the treatment of ccRCC. This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.